Global Vasomotor Symptoms Market

Vasomotor Symptoms Market Size, Share, Growth Analysis, By Therapy type(Hormonal (Estrogen, Progesterone, Combination, Others)), By Distribution Channel(Hospital pharmacies, Retail pharmacies, Online stores, Others), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2784 | Region: Global | Published Date: July, 2024
Pages: 219 | Tables: 62 | Figures: 69

Vasomotor Symptoms Market News

  • In December 2023, Astellas Pharma Inc. announced that the European Commission approved VEOZATM (fezolinetant) 45 mg once daily for treating moderate to severe vasomotor symptoms (VMS) associated with menopause. 

  • In July 2023, Mithra Pharmaceuticals and Searchlight Pharma entered into a licensing agreement for Donesta, an investigational drug for treating menopausal symptoms. Data from two multicenter, randomized Phase III trials (C301 – NCT04209543 and C302 – NCT04090957) evaluating Donesta demonstrated a reduction in vasomotor symptoms from baseline and in comparison, to placebo.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Vasomotor Symptoms Market was valued at USD 3.5 billion in 2022 and is expected to rise from USD 3.74 billion in 2023 to reach a value of USD 6.38 billion by 2031, at a CAGR of 6.90% during the forecast period (2024–2031). 

The competitive environment of the Vasomotor Symptoms market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Astellas Pharma Inc. (Japan) ', 'Pfizer Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Bayer AG (Germany) ', 'AbbVie Inc. (United States) ', 'GlaxoSmithKline plc (United Kingdom) ', 'Johnson & Johnson (United States) ', 'Merck & Co., Inc. (United States) ', 'Sanofi S.A. (France) ', 'Eli Lilly and Company (United States) ', 'Novo Nordisk A/S (Denmark) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Amgen Inc. (United States) ', 'Roche Holding AG (Switzerland) ', 'Bristol-Myers Squibb Company (United States) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Mylan N.V. (United States) ', 'Allergan plc (Ireland) ', 'Endo International plc (Ireland) ', 'Sun Pharmaceutical Industries Ltd. (India)'

Research and development (R&D) programs and clinical trials play an important role in increasing our understanding of the underlying mechanisms of neurological symptoms, including mutations and physiology. This increased understanding could pave the way for more targeted and effective therapies, allowing researchers to work to develop new therapies by further exploring the complexity of neurological disorders through clinical trials contributing to the market’s high compound annual growth rate (CAGR). These trials not only expand the range of treatment options available, but also drive market growth by introducing innovative solutions.

The introduction of new interventions or the development of new treatments has the potential to increase awareness of vasomotor symptoms (VMS) and the importance of effective treatment This improved awareness can lead to actively seeking women symptom relief has increased, thus creating a larger market for VMS treatment Can Companies that specialize in introducing new products or new treatments for VMS stand to gain a competitive advantage in the market. This advantage is especially important if the drug is to establish itself as the treatment of choice for healthcare professionals and patients.

The North America vasomotor symptoms market is valued at US$ 1.6 billion by 2023 and is poised to exhibit a noteworthy growth rate at a compound annual growth rate (CAGR) during the analyzed period. This strong growth is primarily related to syndromes associated with vasomotor issues Besides being due to the readily available knowledge of the availability of relaxing drugs, common symptoms of inflammation widespread around the time of menopause gain market significant impact on development. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Vagus Nerve Stimulation Market
Buy Now GET FREE SAMPLE
Hematology Diagnostics Market
Buy Now GET FREE SAMPLE
Vaginitis Therapeutics Market
Buy Now GET FREE SAMPLE
Allergy Diagnostics Market
Buy Now GET FREE SAMPLE
COVID-19 Diagnostics Market
Buy Now GET FREE SAMPLE
Hemodynamic Monitoring Market
Buy Now GET FREE SAMPLE
Plasmapheresis Market
Buy Now GET FREE SAMPLE
Rapid Diagnostics Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Vasomotor Symptoms Market

Report ID: SQMIG35A2784

$5,300
BUY NOW GET FREE SAMPLE